Critical analysis of rituximab-induced serological changes in connective tissue diseases

被引:30
作者
Cornec, D. [1 ,2 ,3 ,4 ]
Avouac, J. [5 ]
Youinou, P. [1 ,2 ,4 ]
Saraux, A. [1 ,2 ,3 ]
机构
[1] Univ Brest, EA2216, Brest, France
[2] Univ Brest, IRF148, Brest, France
[3] Hop la Cavale Blanche, CHU, Rheumatol Unit, Brest, France
[4] Hop Morvan, Immunol Lab, Brest, France
[5] Hop Cochin, Dept Rheumatol, F-75674 Paris, France
关键词
Rituximab; Connective tissue diseases; Immunoglobulin; Autoantibody; BAFF; B lymphocyte; SYSTEMIC-LUPUS-ERYTHEMATOSUS; B-CELL DEPLETION; ACTIVE RHEUMATOID-ARTHRITIS; PRIMARY SJOGRENS-SYNDROME; ANTI-CD20; TREATMENT; AUTOIMMUNE-DISEASE; TREATED PATIENTS; SALIVARY-GLANDS; DOUBLE-BLIND; THERAPY;
D O I
10.1016/j.autrev.2009.01.007
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A survey of PUBMED and EMBASE supplied 21 articles dealing with the effect of rituximab (RTX) on immunoglobulin (Ig) and autoantibodies (Abs) in nonorgan-systemic autoimmune diseases, and another 12 articles were found by hand search. No statistics could be performed due to the lack of numerical data in the articles. RTX tended to diminish total Ig but still within the normal ranges, more for IgM than IgG and IgA. Rheumatoid factor level decreased by 30 to 60% 3-6 months after RTX, whereas anti-cyclic citrullinated peptide Ab titers declined modestly. In contrast, anti-DNA and anti-C1q Ab levels showed a marked decrease, whereas the other anti-extractable nuclear antigens Ab (anti-SSA, SSB, SM, RNP...) were stable. There are claims for an increase in the BAFF level by approximately 2.5 to 3-fold at 3-4 months, and a return to pre-treatment value at 8-12 months. RTX-induced changes in the serum bring about new insights into mechanisms of action. Therefore, more attention should be paid to such parameters in clinical trials. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:515 / 519
页数:5
相关论文
共 40 条
[1]   Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy [J].
Anolik, Jennifer H. ;
Barnard, Jennifer ;
Owen, Teresa ;
Zheng, Bo ;
Kemshetti, Sunil ;
Looney, R. John ;
Sanz, Inaki .
ARTHRITIS AND RHEUMATISM, 2007, 56 (09) :3044-3056
[2]   Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus [J].
Anolik, JH ;
Barnard, J ;
Cappione, A ;
Pugh-Bernard, AE ;
Felgar, RE ;
Looney, RJ ;
Sanz, I .
ARTHRITIS AND RHEUMATISM, 2004, 50 (11) :3580-3590
[3]   What is the role of rituximab in the treatment of rheumatoid arthritis? [J].
Atzeni, Fabiola ;
Doria, Andrea ;
Maurizio, Turiel ;
Sarzi-Puttini, Piercarlo .
AUTOIMMUNITY REVIEWS, 2007, 6 (08) :553-558
[4]   Does the BAFF dysregulation play a major role in the pathogenesis of systemic lupus erythematosus? [J].
Binard, Aymeric ;
Le Pottier, Laeitia ;
Saraux, Alain ;
Devauchelle-Pensec, Valerie ;
Pers, Jacques-Olivier ;
Youinou, Pierre .
JOURNAL OF AUTOIMMUNITY, 2008, 30 (1-2) :63-67
[5]   Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy [J].
Bokarewa, M. ;
Lindholm, C. ;
Zendjanchi, K. ;
Nadali, M. ;
Tarkowski, A. .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2007, 66 (04) :476-483
[6]   Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis [J].
Cambridge, G ;
Leandro, MJ ;
Edwards, JCW ;
Ehrenstein, MR ;
Salden, M ;
Bodman-Smith, M ;
Webster, ADB .
ARTHRITIS AND RHEUMATISM, 2003, 48 (08) :2146-2154
[7]   B cell depletion therapy in systemic lupus erythematosus - Effect on autoantibody and antimicrobial antibody profiles [J].
Cambridge, G. ;
Leandro, M. J. ;
Teodorescu, M. ;
Manson, J. ;
Rahman, A. ;
Isenberg, D. A. ;
Edwards, J. C. .
ARTHRITIS AND RHEUMATISM, 2006, 54 (11) :3612-3622
[8]   Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment - Relationships with B cell depletion, circulating antibodies, and clinical relapse [J].
Cambridge, G ;
Stohl, W ;
Leandro, MJ ;
Migone, TS ;
Hilbert, DM ;
Edwards, JCW .
ARTHRITIS AND RHEUMATISM, 2006, 54 (03) :723-732
[9]   A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus [J].
Chan, OTM ;
Hannum, LG ;
Haberman, AM ;
Madaio, MP ;
Shlomchik, MJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (10) :1639-1647
[10]   Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks [J].
Cohen, Stanley B. ;
Emery, Paul ;
Greenwald, Maria W. ;
Dougados, Maxime ;
Furie, Richard A. ;
Genovese, Mark C. ;
Keystone, Edward C. ;
Loveless, James E. ;
Burmester, Gerd-Ruediger ;
Cravets, Matthew W. ;
Hessey, Eva W. ;
Shaw, Timothy ;
Totoritis, Mark C. .
ARTHRITIS AND RHEUMATISM, 2006, 54 (09) :2793-2806